Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Jul;57(1):79–84.

Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by 125I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies.

Y Inagaki, T Morizane, S Matsumura, N Kawamura, T Watanabe, N Kumagai, T Nakamura, K Tsuchimoto, M Tsuchiya
PMCID: PMC1536074  PMID: 6540149

Abstract

Antibody binding to living Chang liver cell was measured in sera from 71 patients with various chronic liver diseases using 125I-labelled protein A binding assay. The level of antibody binding to Chang liver cell was significantly elevated in sera from patients with chronic active hepatitis (CAH), chronic persistent hepatitis (CPH) and liver cirrhosis as compared to those from healthy donors, but not in sera from patients with fatty liver. There was no detectable antibody binding to HeLa cells in those sera. The antibody binding to Chang liver cell was blocked by a human liver specific protein (LSP) preparation. The levels of antibody binding to Chang liver cell were significantly higher in patients with CAH than patients with CPH. On the other hand, the level of antibody binding to Chang liver cell was significantly decreased in sera from patients with CAH after a treatment with prednisolone (PSL) for 2 months and a subsequent combined administration of 6MP and a maintenance dose of PSL for 1 month. These results suggest that antibodies to Chang liver cell are closely correlated with the activity of chronic liver disease and that PSL and 6MP treatment can reduce the level of the antibodies.

Full text

PDF
79

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CHANG R. S. M. Continuous subcultivation of epithelial-like cells from normal human tissues. Proc Soc Exp Biol Med. 1954 Nov;87(2):440–443. doi: 10.3181/00379727-87-21406. [DOI] [PubMed] [Google Scholar]
  2. Cochrane A. M., Moussouros A., Thomsom A. D., Eddleston A. L., Wiiliams R. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet. 1976 Feb 28;1(7957):441–444. doi: 10.1016/s0140-6736(76)91472-0. [DOI] [PubMed] [Google Scholar]
  3. Hopf U., Meyer zum Büschenfelde K. H., Arnold W. Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med. 1976 Mar 11;294(11):578–582. doi: 10.1056/NEJM197603112941103. [DOI] [PubMed] [Google Scholar]
  4. Hütteroth T. H., Meyer K. H. Antigenic relationship between Chang liver cells and human hepatocytes. Klin Wochenschr. 1978 May 15;56(10):525–527. doi: 10.1007/BF01492866. [DOI] [PubMed] [Google Scholar]
  5. Kakumu S., Arakawa Y., Goji H., Kashio T., Yata K. Occurrence and significance of antibody to liver-specific membrane lipoprotein by double-antibody immunoprecipitation method in sera of patients with acute and chronic liver diseases. Gastroenterology. 1979 Apr;76(4):665–672. [PubMed] [Google Scholar]
  6. Kawanishi H. In vitro studies on IgG-mediated lymphocyte cytotoxicity in chronic active liver disease. Gastroenterology. 1977 Sep;73(3):549–555. [PubMed] [Google Scholar]
  7. Kawanishi H., MacDermott R. P. K-cell-mediated antibody-dependent cellular cytotoxicity in chronic active liver disease. Gastroenterology. 1979 Jan;76(1):151–158. [PubMed] [Google Scholar]
  8. Lam K. C., Lai C. L., Trepo C., Wu P. C. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med. 1981 Feb 12;304(7):380–386. doi: 10.1056/NEJM198102123040702. [DOI] [PubMed] [Google Scholar]
  9. Langone J. J. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol. 1982;32:157–252. [PubMed] [Google Scholar]
  10. McFarlane I. G., Wojcicka B. M., Zucker G. M., Eddleston A. L., Williams R. Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol. 1977 Mar;27(3):381–390. [PMC free article] [PubMed] [Google Scholar]
  11. Miller J., Smith M. G., Mitchell C. G., Reed W. D., Eddleston A. L., Williams R. Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet. 1972 Aug 12;2(7772):296–297. doi: 10.1016/s0140-6736(72)92904-2. [DOI] [PubMed] [Google Scholar]
  12. Nouri-Aria K. T., Hegarty J. E., Alexander G. J., Eddleston A. L., Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med. 1982 Nov 18;307(21):1301–1304. doi: 10.1056/NEJM198211183072102. [DOI] [PubMed] [Google Scholar]
  13. Thestrup-Pedersen K., Ladefoged K., Andersen P. Lymphocyte transformation test with liver-specific protein and phytohaemagglutinin in patients with liver disease. Clin Exp Immunol. 1976 Apr;24(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  14. Thomas H. C., De Villiers D., Potter B., Hodgson H., Jain S., Jewell D. P., Sherlock S. Immune complexes in acute and chronic liver disease. Clin Exp Immunol. 1978 Feb;31(2):150–157. [PMC free article] [PubMed] [Google Scholar]
  15. Thomson A. D., Cochrane M. A., McFarlane I. G., Eddleston A. L., Williams R. Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature. 1974 Dec 20;252(5485):721–722. doi: 10.1038/252721a0. [DOI] [PubMed] [Google Scholar]
  16. Wands K. R., Isselbacher K. J. Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1301–1303. doi: 10.1073/pnas.72.4.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES